

LISTING OF THE CLAIMS

1. (Previously presented) A method of treating a neoplastic disease in a subject, the method comprising:

administering to a subject having a tumor a pharmaceutically acceptable salt of an inorganic selenium-containing compound (iSe compound) in an amount effective to alter a reduction-oxidation state of a tumor cell toward oxidation; and

administering radiation therapy to the subject within 6 hours after administering the iSe compound;

wherein administering the iSe compound and radiation therapy provides for a synergistic effect in treating the neoplastic disease in the subject.

2. (Original) The method of claim 1, wherein the iSe compound is inorganic selenite.

3. (Cancelled)

4. (Original) The method of claim 1, wherein the neoplastic disease is prostate cancer.

5. (Cancelled)

6. (Previously presented) The method of claim 1, wherein the radiation therapy is external beam radiation therapy, brachytherapy or systemically targeted radiation.

7. (Cancelled)

8. (**Currently Amended**) The method of claim 1, wherein said administering of the iSe compound is intravenous, tumor targeted, intratumoral, or-peritumoral, or oral.

9. (Previously presented) The method of claim 1, wherein the iSe compound is administered within 2 hours prior to administering the radiation therapy.

10. (Previously presented) A method of enhancing sensitivity of a tumor in a subject to radiation therapy, the method comprising:

administering to a subject having a tumor a pharmaceutically acceptable salt of an inorganic selenium-containing compound (iSe compound) in an amount effective to sensitize the tumor to radiation therapy; and

administering the radiation therapy to the subject within 6 hours after administering the iSe compound;

wherein administration of the iSe compound is effective to enhance sensitivity of the tumor to the radiation therapy by providing a synergistic effect in enhancing sensitivity of the tumor to the radiation therapy.

11. (Original) The method of claim 10, wherein inorganic selenium-containing compound is inorganic selenite.

12-14. (Cancelled)

15. (Previously presented) A method of treating prostate cancer, the method comprising:

administering to a subject having prostate cancer a pharmaceutically acceptable salt of an inorganic selenite; and

administering radiation therapy to the subject within 6 hours after administering the pharmaceutically acceptable salt of an inorganic selenite;

wherein administering the pharmaceutically acceptable salt of an inorganic selenite and the radiation therapy provides for a synergistic effect in prostate cancer cell growth inhibition to treat the prostate cancer.

16-18. (Cancelled)

19. (Previously presented) The method of claim 1, wherein the iSe compound is selenite.
20. (Previously presented) The method of claim 19, wherein the pharmaceutically acceptable salt of the iSe compound is a sodium salt.
21. (Previously presented) The method of claim 4, wherein the prostate cancer is androgen-responsive.
22. (Previously presented) The method of claim 4, wherein the prostate cancer is androgen-resistant.
23. (Previously presented) The method of claim 10, wherein the tumor is associated with prostate cancer.
24. (Previously presented) The method of claim 23, wherein the prostate cancer is androgen-responsive.
25. (Previously presented) The method of claim 23, wherein the prostate cancer is androgen- resistant.
26. (Previously presented) The method of claim 10, wherein the radiation therapy is external beam radiation therapy, brachytherapy or systemically targeted radiation.
27. (**Currently amended**) The method of claim 10, wherein the administering of the iSe compound is intravenous, tumor targeted, intratumoral, or-peritumoral, or oral.
28. (Previously presented) The method of claim 15, wherein the radiation therapy is external beam radiation therapy, brachytherapy or systemically targeted radiation.

29. (Currently amended) The method of claim 15, wherein the administering of the iSe compound is intravenous, tumor targeted, intratumoral, or peritumoral, or oral.

30. (Previously presented) The method of claim 1, wherein the iSe compound is inorganic selenate.

31. (Previously presented) The method of claim 1, wherein the administering comprises intravenously administering about 0.25 mg/Kg of the pharmaceutically acceptable salt of iSe compound.

32. (Previously presented) The method of claim 10, wherein the administering comprises intravenously administering about 0.25 mg/Kg or more of the pharmaceutically acceptable salt of iSe compound.

33. (Previously presented) The method of claim 15, wherein the administering comprises intravenously administering about 0.25 mg/Kg or more of the pharmaceutically acceptable salt of an inorganic selenite.